219 related articles for article (PubMed ID: 18636786)
21. Long-term proton pump inhibitor therapy and risk of hip fracture.
Yang YX; Lewis JD; Epstein S; Metz DC
JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
[TBL] [Abstract][Full Text] [Related]
22. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for
Cheung KS; Chan EW; Wong AYS; Chen L; Wong ICK; Leung WK
Gut; 2018 Jan; 67(1):28-35. PubMed ID: 29089382
[TBL] [Abstract][Full Text] [Related]
23. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs.
Eurich DT; Sadowski CA; Simpson SH; Marrie TJ; Majumdar SR
Am J Med; 2010 Jan; 123(1):47-53. PubMed ID: 20102991
[TBL] [Abstract][Full Text] [Related]
24. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
Yu EW; Bauer SR; Bain PA; Bauer DC
Am J Med; 2011 Jun; 124(6):519-26. PubMed ID: 21605729
[TBL] [Abstract][Full Text] [Related]
25. Acid-suppressing therapies and subsite-specific risk of stomach cancer.
Wennerström ECM; Simonsen J; Camargo MC; Rabkin CS
Br J Cancer; 2017 Apr; 116(9):1234-1238. PubMed ID: 28350791
[TBL] [Abstract][Full Text] [Related]
26. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies.
Liu P; McMenamin ÚC; Johnston BT; Murchie P; Iversen L; Lee AJ; Vissers PAJ; Cardwell CR
Br J Cancer; 2020 Jul; 123(2):307-315. PubMed ID: 32367073
[TBL] [Abstract][Full Text] [Related]
27. Use of proton pump inhibitors for the risk of gastric cancer.
Gao H; Li L; Geng K; Teng C; Chen Y; Chu F; Zhao Y
Medicine (Baltimore); 2022 Dec; 101(49):e32228. PubMed ID: 36626449
[TBL] [Abstract][Full Text] [Related]
28. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
29. Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study.
Bradley MC; Murray LJ; Cantwell MM; Hughes CM
Br J Cancer; 2012 Jan; 106(1):233-9. PubMed ID: 22108522
[TBL] [Abstract][Full Text] [Related]
30. The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis.
Song HJ; Jeon N; Squires P
Eur J Clin Pharmacol; 2020 Oct; 76(10):1437-1456. PubMed ID: 32548678
[TBL] [Abstract][Full Text] [Related]
31. Histamine-2-receptor antagonists and gastric cancer risk.
La Vecchia C; Negri E; D'Avanzo B; Franceschi S
Lancet; 1990 Aug; 336(8711):355-7. PubMed ID: 1975342
[TBL] [Abstract][Full Text] [Related]
32. Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case-control study.
Miyano S; Michihata N; Sada KE; Uda K; Matsui H; Fushimi K; Nangaku M; Yasunaga H
Rheumatology (Oxford); 2021 Apr; 60(4):1717-1723. PubMed ID: 33067623
[TBL] [Abstract][Full Text] [Related]
33. Proton pump inhibitors: bacterial pneumonia.
Prescrire Int; 2012 Sep; 21(130):210-2. PubMed ID: 23016253
[TBL] [Abstract][Full Text] [Related]
34. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
35. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.
Dial S; Delaney JA; Barkun AN; Suissa S
JAMA; 2005 Dec; 294(23):2989-95. PubMed ID: 16414946
[TBL] [Abstract][Full Text] [Related]
36. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.
Lam JR; Schneider JL; Quesenberry CP; Corley DA
Gastroenterology; 2017 Mar; 152(4):821-829.e1. PubMed ID: 27890768
[TBL] [Abstract][Full Text] [Related]
37. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis.
Eom CS; Jeon CY; Lim JW; Cho EG; Park SM; Lee KS
CMAJ; 2011 Feb; 183(3):310-9. PubMed ID: 21173070
[TBL] [Abstract][Full Text] [Related]
38. Use of proton pump inhibitors and risk of pancreatic cancer.
Hicks B; Friis S; Pottegård A
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):926-930. PubMed ID: 29923251
[TBL] [Abstract][Full Text] [Related]
39. Proton pump inhibitors and risk of gastric cancer: population-based cohort study.
Abrahami D; McDonald EG; Schnitzer ME; Barkun AN; Suissa S; Azoulay L
Gut; 2022 Jan; 71(1):16-24. PubMed ID: 34226290
[TBL] [Abstract][Full Text] [Related]
40. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk?
Garcia Rodríguez LA; Ruigómez A
Epidemiology; 1997 Sep; 8(5):571-4. PubMed ID: 9270961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
